ABI
CNC icon

Adamant Biomedical Investments’s Centene CNC Stock Holding History

Adamant Biomedical Investments’s Portfolio CNC Stock Details CNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$5.36M Sell
206,440
-107,400
-34% -$2.51M 1.28% 26
2014
Q3 		$6.49M Buy
+313,840
New +$6.05M 1.62% 18

Other funds holding CNC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SAM
Southernsun Asset Management Memphis, Tennessee $690M AUM 30.68% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Adamant Biomedical Investments's CNC Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its Centene (CNC) stake by 34% in Q4 2014, selling an estimated $2.51M and leaving 206,440 shares worth $5.36M. The position accounts for 1.28% of the portfolio, ranked #26.

Adamant Biomedical Investments first reported a position in CNC in Q3 2014 and has held it in 2 quarters since. The position peaked at $6.49M in Q3 2014. 358 funds tracked by Wall St. Rank hold CNC as of Q4 2014.

  • Adamant Biomedical Investments held 206,440 shares of Centene worth $5.36M as of Q4 2014.
  • Adamant Biomedical Investments sold 107,400 Centene shares in Q4 2014, an estimated $2.51M.
  • Centene made up 1.28% of Adamant Biomedical Investments's portfolio in Q4 2014, its #26 holding.
  • Adamant Biomedical Investments first reported a position in Centene in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Centene position peaked at $6.49M in Q3 2014.
  • 358 funds tracked by Wall St. Rank held Centene as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.